Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | RAPA-201 |
| Synonyms | |
| Therapy Description |
RAPA-201 are autologous rapamycin-resistant T cells, which potentially induce tumor cell killing (NCI Drug Dictionary). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| RAPA-201 | RAPA 201|RAPA201 | RAPA-201 are autologous rapamycin-resistant T cells, which potentially induce tumor cell killing (NCI Drug Dictionary). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT06708455 | Phase II | RAPA-201 | Phase 2b of RAPA-201 Cell Therapy in Post-PD-(L)-1 Melanoma | Not yet recruiting | USA | 0 |
| NCT05144698 | Phase II | RAPA-201 | RAPA-201 Therapy of Solid Tumors | Recruiting | USA | 0 |
| NCT04176380 | Phase II | RAPA-201 | RAPA-201 T Cell Therapy for Relapsed, Refractory Multiple Myeloma | Completed | USA | 0 |